EPS for Advaxis, Inc. (ADXS) Expected At $-0.41

May 24, 2018 - By Marie Mckinney

Advaxis, Inc. (NASDAQ:ADXS) LogoInvestors sentiment decreased to 1.12 in Q4 2017. Its down 0.11, from 1.23 in 2017Q3. It turned negative, as 17 investors sold Advaxis, Inc. shares while 17 reduced holdings. 16 funds opened positions while 22 raised stakes. 15.17 million shares or 10.45% less from 16.94 million shares in 2017Q3 were reported.
The New York-based Alliancebernstein Lp has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Citigroup invested in 0% or 6,404 shares. Zacks Inv Mgmt holds 0% or 12,317 shares. Focused Wealth Mngmt Inc owns 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 275 shares. 17,431 are owned by Parametric Port Assoc Ltd Llc. California State Teachers Retirement reported 58,649 shares or 0% of all its holdings. Millennium Management has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Balyasny Asset Management Limited Liability Company accumulated 21,442 shares or 0% of the stock. Parallax Volatility Advisers L P has invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Stonebridge Capital Mngmt holds 0.04% in Advaxis, Inc. (NASDAQ:ADXS) or 37,595 shares. United Cap Fincl Advisers Limited Com invested 0% in Advaxis, Inc. (NASDAQ:ADXS). State Street Corp reported 0% in Advaxis, Inc. (NASDAQ:ADXS). Aqr Mgmt Lc owns 86,208 shares or 0% of their US portfolio. Prelude Management Limited Liability Co reported 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Morgan Stanley holds 0% or 178,381 shares in its portfolio.

Since December 29, 2017, it had 0 buys, and 3 sales for $20,259 activity. Bonstein Sara sold $16,612 worth of Advaxis, Inc. (NASDAQ:ADXS) on Friday, December 29. On Thursday, March 29 PETIT ROBERT sold $3,553 worth of Advaxis, Inc. (NASDAQ:ADXS) or 2,193 shares.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.41 EPS on June, 5.They anticipate $0.10 EPS change or 19.61 % from last quarter’s $-0.51 EPS. After having $-0.49 EPS previously, Advaxis, Inc.’s analysts see -16.33 % EPS growth. The stock increased 0.55% or $0.01 during the last trading session, reaching $1.83. About 382,080 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 77.70% since May 24, 2017 and is downtrending. It has underperformed by 89.25% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 3 analyst reports since December 27, 2017 according to SRatingsIntel. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) on Wednesday, March 14 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, December 27 report. The rating was maintained by Cantor Fitzgerald on Tuesday, March 13 with “Overweight”.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $95.73 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

More news for Advaxis, Inc. (NASDAQ:ADXS) were recently published by: Nasdaq.com, which released: “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …” on May 14, 2018. Businesswire.com‘s article titled: “Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent” and published on May 11, 2018 is yet another important article.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.